Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammation.
Stampanoni Bassi M, Gilio L, Galifi G, Buttari F, Dolcetti E, Bruno A, Belli L, Modugno N, Furlan R, Finardi A, Mandolesi G, Musella A, Centonze D, Olivola E. Stampanoni Bassi M, et al. Among authors: belli l. Parkinsonism Relat Disord. 2024 May;122:106071. doi: 10.1016/j.parkreldis.2024.106071. Epub 2024 Feb 28. Parkinsonism Relat Disord. 2024. PMID: 38432021 Free article.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Frailty among Alzheimer's disease patients.
Koch G, Belli L, Giudice TL, Lorenzo FD, Sancesario GM, Sorge R, Bernardini S, Martorana A. Koch G, et al. Among authors: belli l. CNS Neurol Disord Drug Targets. 2013 Jun;12(4):507-11. doi: 10.2174/1871527311312040010. CNS Neurol Disord Drug Targets. 2013. PMID: 23574166 Review.
Is cerebral glucose metabolism related to blood-brain barrier dysfunction and intrathecal IgG synthesis in Alzheimer disease?: A 18F-FDG PET/CT study.
Chiaravalloti A, Fiorentini A, Francesco U, Martorana A, Koch G, Belli L, Toniolo S, Di Pietro B, Motta C, Schillaci O. Chiaravalloti A, et al. Among authors: belli l. Medicine (Baltimore). 2016 Sep;95(37):e4206. doi: 10.1097/MD.0000000000004206. Medicine (Baltimore). 2016. PMID: 27631200 Free PMC article.
Comparison between Early-Onset and Late-Onset Alzheimer's Disease Patients with Amnestic Presentation: CSF and (18)F-FDG PET Study.
Chiaravalloti A, Koch G, Toniolo S, Belli L, Lorenzo FD, Gaudenzi S, Schillaci O, Bozzali M, Sancesario G, Martorana A. Chiaravalloti A, et al. Among authors: belli l. Dement Geriatr Cogn Dis Extra. 2016 Apr 5;6(1):108-19. doi: 10.1159/000441776. eCollection 2016 Jan-Apr. Dement Geriatr Cogn Dis Extra. 2016. PMID: 27195000 Free PMC article.
Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State.
Martorana A, Di Lorenzo F, Belli L, Sancesario G, Toniolo S, Sallustio F, Sancesario GM, Koch G. Martorana A, et al. Among authors: belli l. CNS Neurosci Ther. 2015 Dec;21(12):921-5. doi: 10.1111/cns.12476. Epub 2015 Nov 11. CNS Neurosci Ther. 2015. PMID: 26555572 Free PMC article. Review.
Insulin and the Future Treatment of Alzheimer's Disease.
Semprini R, Koch G, Belli L, Lorenzo FD, Ragonese M, Manenti G, Sorice GP, Martorana A. Semprini R, et al. Among authors: belli l. CNS Neurol Disord Drug Targets. 2016;15(6):660-4. doi: 10.2174/1871527315666160518123049. CNS Neurol Disord Drug Targets. 2016. PMID: 27189471 Review.
334 results